Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes

Kidney International

Volumn 70, Issue 1, 2006, Pages 177-186

  Tonolo, G ^a   Velussi, M ^b   Brocco, E ^c   Abaterusso, C ^d   Carraro, A ^e   Morgia, G ^f   Satta, A ^f   Faedda, R ^f   Abhyankar, A ^g   Luthman, H ^g   Nosadini, R ^f,h  

^a UODiabetologia ASL 2   (Italy)

^b Ospedale Civile di Monfalcone   (Italy)

^c Diabetic Clinic of Abano   (Italy)

^d Nephrology Department   (Italy)

^e USL San Dona   (Italy)

^f UNIVERSITY OF SASSARI   (Italy)

^g MAS   (Sweden)

^h NONE   (Italy)

Author keywords

C reactive protein; Cholestyramine; Glomerular filtration rate; Microalbuminuria; Oxidized LDL; Podocytes; Simvastatin; Slit diaphragm proteins; Type II diabetes

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; ATENOLOL; C REACTIVE PROTEIN; CD2 ASSOCIATED PROTEIN; CELL PROTEIN; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN DERIVATIVE; INTERLEUKIN 6; LISINOPRIL; LONG ACTING INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; METFORMIN; NEPHRIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PODOCIN; PROTEIN ACTN4; RAMIPRIL; SIMVASTATIN; SLIT DIAPHRAGM PROTEIN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; URINARY EXCRETION;

AGED; ALBUMINS; ALBUMINURIA; ANTICHOLESTEREMIC AGENTS; CHOLESTYRAMINE; DEOXYGUANOSINE; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY GLOMERULUS; LIPIDS; MALE; MIDDLE AGED; PODOCYTES; PROTEINS; RNA, MESSENGER; SIMVASTATIN;

EID: 33745711911     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001515     Document Type: Article

References (39)

1. Excerpts from US. Renal data system annual data report. Am J Kidney Dis 1998; 32: S9-S141.
2. Fabre J, Balant LP, Dayer PG et al. The kidney in maturity onset diabetes mellitus: a clinical study of 510 patients. Kidney Int 1982; 21: 730-738.
3. Kunzelman CL, Knowler WC, Pettitt DJ et al. Incidence of nephropathy in type II diabetes mellitus in the Pima Indians. Kidney Int 1989; 35: 681-687.
4. Nosadini R, Velussi M, Brocco E et al. Course of renal function in type II diabetic patients with abnormalities of albumin excretion rate. Diabetes 2000; 49: 476-484.
5. Perkins BA, Ficocello LH, Silva KH et al. Regression of microalbuminuria in type I diabetes. N Engl J Med 2003; 348: 2285-2293.
6. DCCT. Research Group Diabetes Control and Complications Trial (DCCT) update. Diabetes Care 1990; 13: 427-433.
7. Lewis E, Huinsiker L, Bain R, Rohde R. The effects of angiotensin converting enzyme inhuition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
8. Brenner BM, Cooper M, De Zeeuw D et al. Efects of Losartan on renal and cardiovascular outcomes in patients with type II diabetes mellitus and nephropathy. N Engl J Med 2001; 345: 861-869.
9. Lewis E, Hunsicker L, Clarke W et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to diabetes mellitus. N Engl J Med 2001; 345: 851-860.
10. Barnett A, Bain S, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibtion in type II diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961.
11. Tonolo G, Ciccarese M, Brizzi P et al. Reduction of albumin excretion rate in normotensive microalbuminuric type II diabetic patients during long-term simvastatin treatment. Diabet Care 1997; 20: 1891-1895.
12. Tonolo G, Melis MG, Formato M et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type II diabetic patients. Eur J Clin Invest 2000; 30: 980-987.
13. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-269.
14. Van Wijk B, Buirma R, van Tal A et al. Effects of increasing doses of simvastatin on fasting lipoprotein subfractions and the effects of high dose simvastatin on post prandial chylomicron remnant clearance in normotriglyceridemic patients with premature coronary sclerosis. Atherosclerosis 2005; 178: 147-155.
15. Pearson T, Mensah G, Alexander R et al. American Heart Association guide for improving cardiovascular health at the community level: a statement for public health practitioners, health care providers and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 2003; 107: 645-651.
16. Nosadini R, Velussi M, Brocco E et al. Altered transcapillary escape of albumin and microalbuminuria reflects two different pathogenetic mechanisms. Diabetes 2005; 54: 228-233.
17. Kerjaschki D. Caught flat-footed: podocyte damage and the molecular bases of focal glomerusclerosis. J Clin Invest 2001; 108: 1583-1587.
18. Tryggvason K, Wartiovaara J. Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypert 2001; 10: 543-549.
19. Endlich K, Kriz W, Witzgall R. Update in podocyte biology. Curr Opin Nephrol Hypert 2001; 10: 331-340.
20. Schwarz KS et al. Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest 2001; 108: 1621-1629.
21. Ehrenstein M, Jury E, Mauri C. Statins for atherosclerosis - as good as it gets? N Engl J Med 2005; 352: 73-74.
22. Kasai H. A new automated method to analyze urinary 8- hydroxydeoxyguanosine by a high-performance liquid chromatography- electrochemical detector system. J Radiat Res 2003; 44: 185-189.
23. Kasai H. Analysis of a form of oxidative DNA damage, 8-hydroxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat Res 1997; 387: 147-163.
24. Pocock SJ. Clinical Trials. A Practical Approach. John Wiley & Sons: London, 1983, p 129.
25. Kohen R, Nyska A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions and methods for their quantification. Toxicol Pathol 2002; 30: 620-650.
26. Kasai H, Nishimura S. Hydroxylation of deoxyguanosine at the C-8 position by ascorbic acid and other reducing agents. Nucl Acids Res 1984; 12: 2137-2145.
27. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005; 54: 1-7.
28. Tryggvason K, Patrakka J, Wartiovaara J. Mechanisms of disease: hereditary proteinuria. N Engl J Med 2006; 354: 1387-1401.
29. Larsen K. Creatinine assay by a reaction-kinetic principle. Clin Chim Acta 1972; 41: 209-217.
30. The Merck Manual 17th Edition Published by Merck Research Laboratories, Whitehouse Station NJ, USA 1999, Beers MH, Berkow R eds. Geriatric Medicine, p 2503.
31. Sambataro M, Thomaseth K, Pacini G et al. Plasma clearance rate of 51Cr-EDTA provides a precise and convenient technique for measurement of glomerular filtration rate in diabetic humans. J Am S Nephrol 1996; 7: 118-127.
32. Lemley KV, Boothroyd DB, Blouch KL et al. Modeling GFR trajectories in diabetic nephropathy. Am J Physiol Renal Physiol 2005 May 17; [E-pub ahead of print] [PubMed - as supplied by publisher].
33. Calabresi L, Donati D, Pazzacuoni F et al. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis 2000; 148: 387-396.
34. Pirro M, Bergeron J, Dagenais GR et al. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med 2001; 161: 2474-2480.
35. Bastard JP, Jardel C, Bruckert E et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000; 85: 3338-3342.
36. Mauer M, Steffes M, Ellis E et al. Structural functional relationships in diabetic nephropathy. J Clin Invest 1984; 74: 1143-1155.
37. Fioretto P, Sambataro M, Abaterusso C et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996; 39: 1569-1576.
38. Mundel P, Heid HW, Mundel TM, Kruger M et al. Synaptopodin: an actin-associated protein in telencephalic dendrites and renal podocytes. J Cell Biol 1997; 6: 193-204.
39. Jialal I, Freeman D, Grundy S. Varying susceptibility of different LDL to oxidative modification. Atheroscler Thromb 1991; 11: 482-488.